Virginia Retirement Systems Sells 647,400 Healthpeak Properties Shares, Cuts Stake 84.8%
Virginia Retirement Systems cut its Healthpeak Properties stake by 84.8% in Q3, selling 647,400 shares and retaining 115,940 shares valued at $2.22M. Healthpeak reported Q3 EPS of $0.46 beating consensus by $0.01 on $705.87M revenue and set FY25 EPS guidance at $1.81–$1.87, supporting its 7.5% dividend yield.
1. Significant Stake Reduction by Virginia Retirement Systems
In the third quarter, Virginia Retirement Systems and affiliated accounts slashed their position in Healthpeak Properties by 84.8%, disposing of 647,400 shares and retaining just 115,940 shares valued at $2.22 million at quarter end. This dramatic divestment underscores shifting institutional confidence and reduces their weighting in the REIT’s shareholder base to a minor fraction of total holdings. Overall, institutional and hedge fund ownership stands at 93.57%, but this move by a major public pension plan may signal a reassessment of risk exposure to healthcare real estate amid evolving demographic and interest rate pressures.
2. Third-Quarter Operating Results and FY Guidance
Healthpeak reported third-quarter revenue of $705.87 million, topping consensus by $24.22 million and marking a 0.8% year-over-year increase. Adjusted EPS came in at $0.46, beating estimates by $0.01. Despite a negative net margin of 1.36% and return on equity of -0.44%, management affirmed full-year 2025 EPS guidance of $1.810 to $1.870. The firm reiterated its strategy to recycle proceeds from non-core asset dispositions into higher-return life science and medical office investments, targeting double-digit unlevered IRRs on future deployments.
3. Robust Dividend and Yield Profile
On December 30, Healthpeak paid its monthly distribution of $0.1017 per share to holders of record as of December 19. This translates to an annualized payout of $1.2204 per share and a yield of approximately 7.5%. While the dividend payout ratio stands at an unusually high -2,440% due to accounting treatments, the REIT’s free cash flow coverage remains solid, supported by stable rent roll from senior housing, life science labs and medical office buildings.
4. Evolving Analyst Ratings and Price Targets
Analyst sentiment toward Healthpeak is mixed, with six Buy recommendations and six Holds, yielding a Moderate Buy consensus. Evercore ISI and Robert W. Baird recently trimmed their targets to $21.00 and $20.00 respectively, while Jefferies downgraded to Hold with a $17.00 target. Cantor Fitzgerald and Raymond James maintain Neutral and Outperform ratings at $20.00 apiece. The consensus price target stands at $20.18, suggesting mid-teens percentage upside potential from current levels, contingent on sector leasing recovery and execution of capital recycling initiatives.